Patents Assigned to Quest Diagnostics
  • IDENTIFICATION AND QUANTITATION OF INSULIN-LIKE GROWTH FACTOR-I VARIANTS BY MASS SPECTROMETRY
    Publication number: 20220299524
    Abstract: Methods are provided for detecting insulin-like growth factor-I (IGF-I) variant(s) in a sample. Methods provided herein are further directed to using the detected ion or ions to determine the presence of IGF1 variant(s) in the sample.
    Type: Application
    Filed: March 17, 2022
    Publication date: September 22, 2022
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Ievgen Motorykin, Nigel Clarke, Michael J. McPhaul, Zengru Wu
  • Cystic fibrosis transmembrane conductance regulator gene mutations
    Patent number: 11447826
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: September 20, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Weimin Sun, Matthew J. McGinniss, Donghui Huang, Arlene Buller, Raymond Fenwick, Mei Peng, Franklin Quan
  • Methods for detecting DNA mutations using Mitra tip extraction
    Patent number: 11441188
    Abstract: The present disclosure provides rapid and non-invasive methods for determining whether a patient exhibiting cancer symptoms, or at risk for hereditary cancers such as breast cancer, ovarian cancer, colon cancer, or skin cancer, will benefit from treatment with one or more therapeutic agents. These methods are based on detecting hereditary cancer-related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device (e.g., MITRA Tip). Kits for use in practicing the methods are also provided.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: September 13, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Heather Sanders, Nigel J. Clarke
  • Methods for detecting DNA mutations using mitra tip extraction
    Patent number: 11441192
    Abstract: The present disclosure provides rapid and non-invasive methods for determining whether a patient exhibiting cancer symptoms, or at risk for hereditary cancers such as breast cancer, ovarian cancer, colon cancer, or skin cancer, will benefit from treatment with one or more therapeutic agents. These methods are based on detecting hereditary cancer-related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device (e.g., MITRA Tip). Kits for use in practicing the methods are also provided.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: September 13, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Heather Sanders, Nigel J. Clarke
  • SYSTEM AND METHOD TO STORE AND DISPENSE IMMUNOASSAY
    Publication number: 20220277257
    Abstract: An inventory storage system including a container with an upper surface, a lower surface, a back wall and a front wall facing a width of the upper surface and the lower surface, a first removal slot disposed between the front wall and the lower surface, and a pair of sidewalls facing a length of the upper and lower surfaces. The container includes dividers defining one or more sections. The container includes pens stored within the sections of the container, the pens including at least a subset of first pens and a subset of second pens, with the subset of first pens is below the subset of second pens. The container includes spacers that prevent the subset of second pens from exiting the container via the first removal slot until the subset of first pens exit the container via the first removal slot.
    Type: Application
    Filed: June 19, 2020
    Publication date: September 1, 2022
    Applicant: Quest Diagnostics Investments LLC
    Inventor: Silvino M. Ferreira
  • METHODS FOR DETECTING HEREDITARY CANCERS
    Publication number: 20220275457
    Abstract: The disclosure relates to a genetic inheritance cancer predisposition panel utilizing targeted capture-based next-generation sequencing—the panel incorporates genes underlying well-characterized cancer syndromes and those associated with increased cancer risk. The disclosure further relates to methods of utilizing the genetic inheritance cancer predisposition panel for determining a cancer risk assessment for individuals with hereditary cancers and/or cancer syndromes.
    Type: Application
    Filed: July 17, 2020
    Publication date: September 1, 2022
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Sun Hee ROSENTHAL, Weimin SUN, Ke ZHANG, Anna GERASIMOVA, Andrew GRUPE, Felicitas LACBAWAN
  • Quantitation of tamoxifen and metabolites thereof by mass spectrometry
    Patent number: 11428682
    Abstract: Provided are methods for determining the amount of tamoxifen and its metabolites in a sample by mass spectrometry. In some aspects, the methods provided herein determine the amount of norendoxifen. In some aspects, the methods provided herein determine the amount of norendoxifen and tamoxifen. In some aspects, the methods provided herein determine the amount of norendoxifen and other tamoxifen metabolites. In some aspects, the methods provided herein determine the amount of tamoxifen, norendoxifen, and other tamoxifen metabolites.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: August 30, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Nigel Clarke
  • Circulating microRNA as a marker for hepatocellular carcinoma
    Patent number: 11421283
    Abstract: Provided herein are methods for the diagnosis, or management of liver diseases, e.g., hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: August 23, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Kevin Qu, Ke Zhang, Maher Albitar
  • Method for direct microbial identification
    Patent number: 11421285
    Abstract: Described herein are methods for direct detection of microbial agent(s) in a polymicrobial sample, such as a biological sample from a human, without culturing the microbial agent(s). The direct detection can identify mixtures of bacteria and/or fungi in the sample. Also described are primer sequences and amplification techniques for performing the direct detection methods.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: August 23, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Erik P. Johnson, Nik Isely, Jamie L. Platt, Martin Siaw, Ron M. Kagen, Dale A. Schwab
  • Compositions and methods for detecting circulating tumor DNA
    Patent number: 11414710
    Abstract: The present technology provides polynucleotide compositions and methods of using the same to detect circulating tumor DNA (ctDNA) in a patient. Kits for use in practicing the methods are also provided.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: August 16, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Suzzette Arnal, Taraneh Angeloni
  • System and method for classification of patients
    Patent number: 11398295
    Abstract: A system (100) for classifying a biological test sample, including a database (112) populated with reference expression data. The reference expression data includes expression levels of a plurality of molecules (polynucleotides or polypeptides), including a set of marker molecules, in a plurality of reference samples. Each reference sample has a pre-assigned value for each of one or more clinically significant variables. The system includes at least one processor (110) and at least one storage medium containing program instructions for execution by said processor (110). The program instructions cause the processor to accept (122) input expression data including a test vector of expression levels of the marker molecules in the biological test sample; and pass the input expression data to one or more analysis programs (130a, 130b, 135).
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: July 26, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventor: Ryan L. Van Laar
  • SYSTEMS AND METHODS TO IDENTIFY MUTATIONS IN MITOCHONDRIAL GENOMES
    Publication number: 20220215901
    Abstract: The present disclosure describes a sequencing system configured to identify structural variants in mitochondrial DNA. Variant callers configured to identify variants in linear genomes (e.g., those found in chromosomes) can fail to properly identify structural variants in mitochondrial DNA. The system and methods can identify structural variants in next generation sequencing data collected from circular, mitochondrial DNA.
    Type: Application
    Filed: May 26, 2020
    Publication date: July 7, 2022
    Applicant: Quest Diagnostics Investments LLC
    Inventor: Anindya Bhattacharya
  • METHODS FOR DETECTING ESTRONE BY MASS SPECTROMETRY
    Publication number: 20220214364
    Abstract: Provided are methods for determining the amount of estrone in a sample using mass spectrometry. The methods generally involve ionizing estrone in a sample and detecting and quantifying the amount of the ion to determine the amount of estrone in the sample.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 7, 2022
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Mildred M. Goldman, Richard E. Reitz
  • Device and method for evaluating amount of biological sample in a specimen container
    Patent number: 11378435
    Abstract: An apparatus and method are provided to evaluate an amount of a biological sample in a specimen container. A fixture has a bottom surface configured to support a specimen container. A reference indicator is disposed at a predetermined height relative to the bottom surface. The reference indicator is configured to facilitate a visual comparison of the reference indicator with a height of a volume of a biological sample in the specimen container.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: July 5, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Christine Amendt, Sevag Bedrosian, Gordon Love, Mkrtich Daniyelyan, Miguel Torrero
  • BCR-ABL VARIANTS
    Publication number: 20220196665
    Abstract: A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.
    Type: Application
    Filed: March 14, 2022
    Publication date: June 23, 2022
    Applicant: Quest Diagnostics Investments LLC
    Inventor: Maher ALBITAR
  • Amyloid beta detection by mass spectrometry
    Patent number: 11360098
    Abstract: Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (A?42) to amyloid beta 40 (A?40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: June 14, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Diana Tran, Darren Weber, Nigel Clarke
  • Apolipoprotein E isotype detection by mass spectrometry
    Patent number: 11361953
    Abstract: Provided are methods for determining the apolipoprotein E (ApoE) phenotype in a sample by mass spectrometry; wherein the ApoE allele(s) present in the sample is determined from the identity of the ions detected by mass spectrometry. In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: June 14, 2022
    Assignee: Quest Diagnostics Investments Incoporated
    Inventors: Darren Weber, Nigel Clarke
  • Methods for detecting lacosamide by mass spectrometry
    Patent number: 11360061
    Abstract: Provided are methods for determining the amount of lacosamide in a sample using mass spectrometry. The methods generally involve ionizing lacosamide in a sample and detecting and quantifying the amount of the ion to determine the amount of lacosamide in the sample.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: June 14, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Beatrisa Boyadzhyan, Karin Thomassian, Anita Dermartirosian, Lou Jambor
  • C peptide detection by mass spectrometry
    Patent number: 11346845
    Abstract: Methods are described for measuring the amount of C peptide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying C peptide in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: May 31, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Nigel Clarke, Zhaohui Chen
  • BCR-ABL truncation mutations
    Patent number: 11345964
    Abstract: Truncation variants of BCR-ABL mRNA that produces BCR-ABL proteins with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is described. Vectors for expressing the truncated gene products are described as well as recombinant cells that express the truncated gene products from cDNA constructs. Also provided are methods compositions and kits for detecting the BCR-ABL truncation variants. Also provided are methods for determining the prognosis of a patient diagnosed as having myeloproliferative disease, and methods for predicting the likelihood for resistance to a treatment with tyrosine kinase inhibitor in a patient diagnosed as having myeloproliferative disease. Additionally, methods for screening BCR-ABL tyrosine kinase domain inhibitors which rely on the recombinant cells are also disclosed.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: May 31, 2022
    Assignee: Quest Diagnostics Investments, LLC
    Inventors: Maher Albitar, Wanlong Ma